Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL384 Target Snapshot

HT-29 · CELL-LINE · Homo sapiens

65,805Compounds
7,669Assays
104Approved Drugs
19,140.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats HT-29 as ChEMBL target CHEMBL384. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
HT-29
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL384
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether HT-29 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHT-29
UniProt AccessionN/A

HT-29

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as HT-29.

Review nameHT-29
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

104
Approved
43
Phase III
71
Phase II
35
Phase I
Assay Mix

Activity Type Distribution

IC5017,580.0
EC501,560.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL265841 11.0 IC50 0.01 Preclinical
CHEMBL90555 11.0 IC50 0.01 Approved
CHEMBL284083 10.98 IC50 0.01047 Preclinical
CHEMBL1806651 10.89 IC50 0.013 Preclinical
CHEMBL290566 10.87 IC50 0.01349 Preclinical
CHEMBL263804 10.86 IC50 0.0138 Preclinical
CHEMBL570414 10.74 IC50 0.018 Preclinical
CHEMBL39541 10.74 IC50 0.018 Clinical
CHEMBL1254819 10.7 IC50 0.02 Preclinical
CHEMBL302363 10.68 IC50 0.021 Preclinical
Distribution

pChEMBL Value Distribution

2961
5.0
2250
5.5
1688
6.0
1265
6.5
858
7.0
577
7.5
392
8.0
219
8.5
205
9.0
55
9.5
pChEMBL
Approved Drugs

Approved Drugs

SELUMETINIB
CHEMBL1614701
Approved 2020
TIRBANIBULIN
CHEMBL571546
Approved 2020
PLITIDEPSIN
CHEMBL451930
Approved 2018
COPANLISIB
CHEMBL3218576
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
PANOBINOSTAT
CHEMBL483254
Approved 2015
OSIMERTINIB
CHEMBL3353410
Approved 2015
BELINOSTAT
CHEMBL408513
Approved 2014
NINTEDANIB
CHEMBL502835
Approved 2014
CERITINIB
CHEMBL2403108
Approved 2014
PONATINIB
CHEMBL1171837
Approved 2012
VEMURAFENIB
CHEMBL1229517
Approved 2011
PAZOPANIB
CHEMBL477772
Approved 2009
VORINOSTAT
CHEMBL98
Approved 2006
SUNITINIB
CHEMBL535
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
ERLOTINIB
CHEMBL553
Approved 2004
MYCOPHENOLIC ACID
CHEMBL866
Approved 2004
IMATINIB
CHEMBL941
Approved 2001
CELECOXIB
CHEMBL118
Approved 1998
TOPOTECAN
CHEMBL84
Approved 1996
GEMCITABINE
CHEMBL888
Approved 1996
IRINOTECAN
CHEMBL481
Approved 1996
DOCETAXEL
CHEMBL3545252
Approved 1995
VINORELBINE
CHEMBL553025
Approved 1994
PACLITAXEL
CHEMBL428647
Approved 1992
PODOFILOX
CHEMBL61
Approved 1990
AMSACRINE
CHEMBL43
Approved 1987
MITOXANTRONE
CHEMBL58
Approved 1987
ETOPOSIDE
CHEMBL44657
Approved 1983
NICLOSAMIDE
CHEMBL1448
Approved 1982
DIGITOXIN
CHEMBL254219
Approved 1982
MITOMYCIN
CHEMBL105
Approved 1981
DAUNORUBICIN
CHEMBL178
Approved 1979
DAUNORUBICIN HYDROCHLORIDE
CHEMBL1563
Approved 1979
DIGOXIN
CHEMBL1751
Approved 1975
DOXORUBICIN
CHEMBL53463
Approved 1974
DOXORUBICIN HYDROCHLORIDE
CHEMBL359744
Approved 1974
PLICAMYCIN
CHEMBL1237054
Approved 1970
CYTARABINE
CHEMBL803
Approved 1969
VINBLASTINE
CHEMBL159
Approved 1965
VINBLASTINE SULFATE
CHEMBL378544
Approved 1965
DACTINOMYCIN
CHEMBL1554
Approved 1964
VINCRISTINE SULFATE
CHEMBL501867
Approved 1963
VINCRISTINE
CHEMBL90555
Approved 1963
FLUOROURACIL
CHEMBL185
Approved 1962
COLCHICINE
CHEMBL107
Approved 1961
METHOTREXATE
CHEMBL34259
Approved 1953
Source · ChEMBL 36 via Core Engine